cannabis
- Home
- cannabis
Public
Opening a new frontier in treating Parkinson’s disease
- Review
- November 11, 2022
Is this the most hated company on the ASX?
- Review
- August 16, 2019
Latest Articles
ECS Botanics secures distribution rights to bring Terphogz’s ‘The Original Z’ cannabis strain to Australia
Medicinal cannabis products producer ECS Botanics (ASX: ECS) has struck an exclusive distribution deal with California-based Terphogz LLC, paving the way for the arrival of the famed cannabis strain ‘The Original Z’ (commonly known as Zkittlez) in Australia. This partnership marks a significant milestone in Australia’s burgeoning medicinal cannabis market, allowing patients access to one
Read MorePublic
Bioxyne leads the way as Australia’s first manufacturer of pharmaceutical cannabis gummies
Pharmaceutical and consumer health company, Bioxyne (ASX: BXN) has become the first manufacturer in Australia to produce cannabis gummies under a Good Manufacturing Practice (GMP) licence. Through its subsidiary, Breathe Life Sciences (BLS), Bioxyne has completed the first commercial run of these pharmaceutical-grade edibles, taking an early position in Australia’s fast-evolving medicinal cannabis market where
Read MorePublic
Melodiol moves to clear debt with $12m asset fire sale
In early 2024, Melodiol Global Health (ASX: ME1), formerly known as Creso Pharma, faced scrutiny from the ASX, regarding corporate governance and financial disclosure which led to a major restructure and rebrand, but now the time has come to offload a major asset in an attempt for survival under its mounting debt obligations. Melodiol is
Read MorePublic
Althea to make a splash in the US with new cannabis-based sodas
First they started brewing cannabis-infused beer, now Althea Group (ASX: AGH) is bringing cans of cannabis-based sodas to the market that will inevitably have certain consumers checking whether they’re tripping. The move is set to shake up the cannabis-based products market as a recreational product that will make a bold entry into the burgeoning US
Read MorePublic
Melodiol Global Health reports revenue growth amid wider acceptance of medicinal cannabis products
Recreational cannabis use has been a global topic for debate in the past few years but cannabinoids, a naturally occurring compound in cannabis, are now gaining momentum as a treatment for managing pain, inflammation and various mental health conditions like depression and PTSD. For the past several months, Melodiol Global Health’s (ASX: ME1) subsidiary, Health
Read MorePublic
Wellnex ventures into medicinal cannabis with it’s new Wellness Life brand
Seeking expansion into the burgeoning medicinal cannabis market as part of the plant’s trend as a treatment for various common ailments, Wellnex Life (ASX: WNX) will debut its new Wellness Life cannabis brand next month. The launch of Wellness Life will be supported by a collaboration with OneLife Botanicals and is bolstered by the appointment
Read MorePublic
